A multimodal investigation of altered cortical metabolism in patients with disorders of consciousness
Abstract
Disorders of consciousness (DoC) are characterised by marked reductions in cerebral glucose metabolism, but the specific cellular and neurochemical processes driving this impairment remain unclear. To elucidate these mechanisms, a multimodal imaging approach combining [ 18 F]-fluorodeoxyglucose positron emission tomography (FDG-PET) and magnetic resonance spectroscopy (MRS) was applied to the posterior medial cortex (PMC) in 15 DoC patients and 14 healthy controls. Regional FDG metabolic index (FDG-MI) values and MRS concentration estimates of glutamate plus glutamine (Glx), γ-aminobutyric acid (GABA+), total N-acetylaspartate (tNAA), total creatine (tCr), and total choline (tCho) were compared between groups and evaluated against Coma Recovery Scale–Revised (CRS-R) scores at baseline and follow-up (mean 127 days). Patients demonstrated reductions within the PMC in Glx, tCr, and tNAA concentrations, as well as a reduced Glx/GABA+ ratio. Local FDG-MI was substantially reduced in patients and correlated positively with tNAA and tCr. Furthermore, baseline tCho concentrations positively predicted long-term clinical recovery, as indexed by changes in CRS-R scores at follow-up. These findings suggest that macroscopic glucose hypometabolism in DoC may be linked to disrupted intracellular mitochondrial energy production pathways and a shift towards relative synaptic inhibition in the PMC. Moreover, the association between choline levels and behavioural recovery may point to the…
Read the paper
Related studies
- Biportal endoscopic versus microscopic lumbar decompressive laminectomy in patients with spinal stenosis: A randomized controlled trial
- A whey protein-based multi-ingredient nutritional supplement stimulates gains in lean body mass and strength in healthy older men: A randomized controlled trial
- Supplement-based nutritional strategies to tackle frailty: A multifactorial, double-blind, randomized placebo-controlled trial
- A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression
- Creatine supplementation (3 g/day) and bone health in older women: a 2-year, randomized, placebo-controlled trial
- A Multi-Ingredient Nutritional Supplement in Combination With Resistance Exercise and High-Intensity Interval Training Improves Cognitive Function and Increases N-3 Index in Healthy Older Men: A Randomized Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.